PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Therapeutics (PTCT) reported $196.79 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 0.1%. EPS of -$1.39 for the same period compares to -$1.76 a year ago.The reported revenue represents a surprise of +13.41% over the Zacks Consensus Estimate of $173.51 million. With the consensus EPS estimate being -$1.54, the EPS surprise was +9.74%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Net product revenue: $135.42 million versus the six-analyst average estimate of $111.28 million. The reported number represents a year-over-year change of -6%. Revenues- Royalty revenue: $61.37 million versus the six-analyst average estimate of $62.95 million. The reported number represents a year-over-year change of +22.3%. Revenues- Net product revenue- Emflaza: $52 million compared to the $36.89 million average estimate based on four analysts. The reported number represents a change of -22.4% year over year. Revenues- Net product revenue- Translarna: $72 million versus $65.30 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change. View all Key Company Metrics for PTC Therapeutics here>>>Shares of PTC Therapeutics have returned +8.1% over the past month versus the Zacks S&P 500 composite's +3.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PTC Therapeutics, Inc. (PTCT): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks